# Subscription Model Architecture - Session Log

**Date Started:** 2026-02-24
**Project:** Alche Pitch Book - Subscription Model Architecture
**Session Owner:** Timu

---

## Session Overview

**Objective:** Build a comprehensive subscription model architecture for alche that answers:
- Which features belong in EUR 19 vs EUR 49 vs EUR 99 tiers?
- What triggers upgrades between tiers?
- How do 6 revenue streams integrate with tier benefits?
- What retention mechanisms defend 8% churn target (vs 12-15% industry)?
- How does physical space tie into tier structure?

**Critical Targets:**
- 4-5% free→paid conversion
- 20% Core→Pro upgrade rate
- 8% monthly churn (vs 12-15% industry)
- EUR 49 weighted ARPU
- 145 subscribers at Month 12 break-even

---

## PHASE 1: Competitive Research & Feature Inventory

### Actions Taken

**Step 1.1:** Created folder structure
- `/01-research/` - Research outputs
- `/02-options/` - Scenario options
- `/03-decisions/` - Decision logs
- `/04-deliverables/` - Final outputs

**Step 1.2:** Launched 3 parallel research agents (general-purpose)
- **Agent A:** Competitor Tier Analyst (Oura, Hims, ZOE, WHOOP)
- **Agent B:** Behavioral Psychology Researcher (upgrade triggers, German WTP, pricing psychology)
- **Agent C:** Feature Inventory Builder (117 alche features catalogued)

### Deliverables Created

1. **`01-research/competitor-analysis.md`**
   - Status: ✅ Complete
   - Agent: a46b6a8
   - Duration: 5.5 minutes
   - Key findings: Oura (2-tier), Hims (treatment-specific), ZOE (test+sub), WHOOP (3-tier annual)

2. **`01-research/behavioral-triggers.md`**
   - Status: ✅ Complete
   - Agent: aa8b549
   - Duration: 5.4 minutes
   - Key findings: 72-hour decision window, 27% German WTP, decoy effect = 70% choose middle tier

3. **`01-research/feature-inventory.md`**
   - Status: ✅ Complete
   - Agent: a7a7619
   - Duration: 3.7 minutes
   - Key findings: 117 features (73 digital, 15 physical, 20 cross-sell, 9 B2B)

---

## APPROVAL GATE 1: Research Quality Review

### Presentation to Timu
**Date:** 2026-02-24
**Time:** [Current session]

**Questions Asked:**
1. Which competitor tier structures resonate with alche's positioning?
2. Which psychological patterns should alche leverage?
3. Any features missing from the inventory?

### Timu's Response
**Request:** Deeper research and fact-checking required before approval.

**Specific Actions Requested:**
- Fact-check all data points from Phase 1
- Deepen research where gaps exist
- Log every step for future reference

**Status:** ⏸️ PAUSED - Awaiting fact-checking completion

---

## PHASE 1B: Fact-Checking & Deep Research

### Actions Completed

**Step 1B.1:** Launched 3 fact-checking agents ✅
- **Agent A:** Competitor Data Fact-Checker (Agent ID: a72c547)
- **Agent B:** Psychology Data Fact-Checker (Agent ID: ae219fc)
- **Agent C:** Feature Data Cross-Checker (Agent ID: a7641b2)

**Step 1B.2:** Fact-check reports generated ✅
- `01-research/fact-check-competitors.md` (competitor pricing verification)
- `01-research/fact-check-psychology.md` (behavioral stats verification)
- `01-research/fact-check-features.md` (feature inventory cross-check)

### Fact-Check Results Summary

#### Agent A: Competitor Data
**Status:** ✅ Complete (3.8 minutes, 21 tool uses)

**Critical Corrections Needed:**
1. **Oura trial period:** Document claims 6 months, ACTUAL is 1 month
2. **ZOE pricing:** Document shows $39-60/mo, ACTUAL is $9.99-24.99/mo (60% price cut)
3. **Hims revenue:** Minor update $2.3B → $2.35B (FY 2025)
4. **WHOOP One:** Two versions exist ($149 vs $199/yr)

**Data Verified:** Oura valuation ($11B, 5.5M rings), Hims subs (2.5M), WHOOP tiers, AG1 revenue

#### Agent B: Psychology Data
**Status:** ✅ Complete (6.1 minutes, 30 tool uses)

**Verification Results:**
- 18 statistics: Fully verified with original sources
- 5 statistics: Verified with contextual notes
- 3 statistics: Unable to locate original sources
- 2 statistics: Partially verified with caveats

**Critical Issues:**
1. **"70% choose middle tier"** - Pricing strategy recommendation, NOT empirical finding
2. **EUR 457.7 preventive care** - Eurostat shows EUR 458 (2022)
3. **"34% guarantee conversion boost"** - Studies show 10-30% range (source unclear)

**Locked Data Verified:** ✅ 27% German WTP (SpringerMedizin), ✅ 8% EU data sharing (BEUC)

#### Agent C: Feature Inventory
**Status:** ✅ Complete (4.8 minutes, 15 tool uses)

**Overall Assessment:** 8.5/10 — SUBSTANTIALLY ACCURATE

**Critical Corrections:**
1. **Positioning error:** "Digital AND physical first" should be "Digital-first, physical as acquisition channel"
2. **Double-counting:** B2B features counted twice (cross-sell + patient-facing)
3. **Missing features:** 7 identified (waitlist page, founding member pricing, payment infra, lab partnerships, etc.)
4. **Phase timing:** Conflates pre-funding quarterly talks with Phase 2 physical space

**Corrected Counts:**
- Digital: 69 (not 73)
- Physical: 17 (not 15)
- Cross-sell: 16 (not 20)
- Total: ~111 unique features (not 117)

### Deeper Research Required

**From Competitor Analysis:**
- ZOE's 60% price cuts and business model pivot (what does this signal for market?)
- WHOOP's FDA regulatory challenges (relevant for alche's CGM/medical positioning?)

**From Psychology Research:**
- German annual vs monthly pricing sensitivity (only 13.8% monthly users active after year)
- Founder pricing effectiveness for Berlin tech workers specifically

**From Feature Inventory:**
- V1 AI/ML feasibility: Can 7 AI features ship in 3 months (M7-9)?
- Premium tier economics: EUR 99 with physician calls = 17-25% COGS. Sustainable?
- Walk-in conversion claims: "60% acquisitions from physical at EUR 15-20 CAC" - source?
- CGM regulatory path: Physician required (regulatory) or preferred (credibility)?

---

## Communication Log

### 2026-02-24 - Initial Plan Approval
**From:** User (Plan document)
**To:** Claude
**Content:** Implement Phase 1 of subscription model architecture plan
**Action:** Launched Phase 1 research agents

### 2026-02-24 - Phase 1 Complete
**From:** Claude
**To:** Timu
**Content:** Presented 3 research deliverables for approval
**Questions:** Competitor structure preference, psychological patterns, feature gaps

### 2026-02-24 - Fact-Check Request
**From:** Timu
**To:** Claude
**Content:** "deeper research and fact check. also log every step we made by communicating me for future reference."
**Action:** Creating logging system + launching fact-checking agents

### 2026-02-24 - Fact-Check Complete
**From:** Claude
**To:** Timu
**Content:** Presented fact-check summary with 3 verification reports
**Files Created:**
- `SESSION_LOG.md` (this file)
- `FACT_CHECK_SUMMARY.md` (decision point)
- `01-research/fact-check-competitors.md` (competitor data verification)
- `01-research/fact-check-psychology.md` (behavioral stats verification)
- `01-research/fact-check-features.md` (feature inventory cross-check)

**Status:** ⏸️ AWAITING DECISION - Option A/B/C/D for next steps

---

## Next Steps

1. ✅ Create SESSION_LOG.md (this file)
2. 🔄 Launch fact-checking agents (in progress)
3. ⏸️ Present fact-check results to Timu
4. ⏸️ Get approval before Phase 2
5. ⏸️ Continue to tier allocation options

---

## Decision Points (To Be Logged)

**Gate 1:** Research quality approval
- Status: Pending fact-check completion
- Decision needed: Approve Phase 1 research OR request further revisions

**Gate 2:** Tier allocation scenario selection
- Status: Not yet reached
- Decision needed: [TBD]

**Gate 3:** Retention research approval
- Status: Not yet reached
- Decision needed: [TBD]

[Additional gates will be documented as we progress]

---

**Last Updated:** 2026-02-24 (Step 1B.1 - Fact-checking launch)
